Fig. 5

Power to detect differences in liver burden comparing a candidate mAb to AB311 administered at single dose (ID50 of AB311) for varying sample sizes and experimental variation (standard deviations of log₁₀ flux). Candidate mAbs were varied by increasing potency (fold reduction in log₁₀ flux compared AB311). Given a fold reduction in flux at a single dose, the fold reduction in ID50 (top axis) was estimated using the dose–response relationships (4PL models) estimated for AB317, representing a potential candidate mAb. The vertical dashed-line was the estimated fold reduction in ID50 comparing AB317 to AB311 (1.50-fold, Table 3)